Clinical Trial Update: A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety, tolerability, and pharmacodynamics of PF-06882961 in adults with type 2 diabetes mellitus and non-diabetic adults with o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• PF-06882961

Snippet

Sponsor: Pfizer | Conditions: Diabetes, Obesity | Phase 2 | Status: COMPLETED | Results posted: 2022-12-08